Key points:
- Ionis and Biogen are two companies that work together to make drugs for diseases that affect the nerves, like ALS and Angelman Syndrome.
- They stopped developing a drug for ALS because it did not help people with the disease get better or feel more comfortable.
- They also decided not to develop another drug for Angelman Syndrome, but they did not say why.
- Despite these setbacks, they have made other successful drugs together and are still working on new ones for nerve diseases like Alzheimer's and Parkinson's. Read from source...

1. The headline is misleading and sensationalized. It does not accurately reflect the main point of the article, which is that Biogen decided to end the development of a drug for ALS after seeing disappointing results from a phase I/II study. Instead, it implies that both drugs (BIIB105 and BIIB121) were unsuccessful or discontinued due to safety issues, which is not true.
2. The article focuses too much on the negative aspects of the situation, while ignoring potential positive outcomes for both companies. For example, it does not mention that Ionis will continue to develop BIIB121 independently, or that Biogen and Ionis have a history of successful collaborations in the ALS space, such as Spinraza and Qalsody.
3. The article uses vague and ambiguous terms to describe the study results, such as "did not achieve a reduction" and "failed to demonstrate an impact". These phrases suggest that the drugs had no effect at all, when in reality they may have shown some activity or potential for further development. A more accurate and objective way to report the findings would be to provide specific data and numerical results from the study, such as the exact levels of NfL or the magnitude of changes in clinical outcome measures.
4. The article includes irrelevant information about Biogen's share price performance compared to the industry average, which does not directly relate to the quality or potential of the drugs being developed. This seems like an attempt to manipulate the reader's emotions and create a negative impression of Biogen as a company.
5. The article ends with a brief mention of other ongoing collaborations between Biogen and Ionis, but does not provide any details or updates on their progress or potential value for patients or investors. This creates a sense of uncertainty and leaves the reader wondering what the future holds for these partnerships.